Short Interest in Eterna Therapeutics Inc. (NASDAQ:ERNA) Expands By 10.2%

Eterna Therapeutics Inc. (NASDAQ:ERNA) saw a significant growth in short interest in September. As of September 15th, there was short interest totalling 36,600 shares, a growth of 10.2% from the August 31st total of 33,200 shares. Based on an average trading volume of 8,900 shares, the short-interest ratio is currently 4.1 days. Currently, 1.3% of the shares of the company are short sold.

Eterna Therapeutics Stock Performance

Shares of ERNA traded down $0.05 during mid-day trading on Tuesday, hitting $1.00. 17,779 shares of the company’s stock were exchanged, compared to its average volume of 13,618. Eterna Therapeutics has a fifty-two week low of $0.84 and a fifty-two week high of $2.63. The firm has a market capitalization of $5.41 million, a P/E ratio of -0.23 and a beta of 4.43. The business’s 50 day moving average is $1.64 and its two-hundred day moving average is $1.89. The company has a current ratio of 0.37, a quick ratio of 0.37 and a debt-to-equity ratio of 3.03.

Eterna Therapeutics (NASDAQ:ERNA) last announced its earnings results on Tuesday, August 13th. The company reported ($1.02) earnings per share for the quarter. Eterna Therapeutics had a negative return on equity of 1,466.71% and a negative net margin of 14,765.43%. The business had revenue of $0.05 million for the quarter.

Institutional Investors Weigh In On Eterna Therapeutics

Hedge funds have recently made changes to their positions in the business. Avidian Wealth Solutions LLC purchased a new position in Eterna Therapeutics during the first quarter worth about $36,000. Sippican Capital Advisors increased its holdings in Eterna Therapeutics by 34.7% in the first quarter. Sippican Capital Advisors now owns 72,800 shares of the company’s stock valued at $175,000 after buying an additional 18,750 shares in the last quarter. Finally, Lake Street Advisors Group LLC purchased a new position in Eterna Therapeutics in the fourth quarter valued at about $933,000. Institutional investors and hedge funds own 70.55% of the company’s stock.

About Eterna Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.